AC Immune to Showcase Anti-Tau Portfolio at H.C. Wainwright 22nd Annual Global Investment Conference
AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will showcase recent progress in its clinical programs targeting Tau for neurodegenerative diseases at the upcoming H.C. Wainwright 22nd Annual Global Investment Conference.